dipyridamole has been researched along with Disease Models, Animal in 114 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our findings show that the use of dipyridamole before testicular reperfusion has a potentially protective effect against long-term injury in testicular ischemia reperfusion injury." | 7.78 | Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury. ( Karagüzel, E; Kazaz, İO; Kutlu, Ö; Mungan, S; Özgür, GK; Tok, DS; Yuluğ, E, 2012) |
| "Dipyridamole anti-platelet therapy has previously been suggested to ameliorate chronic tissue ischemia in healthy animals." | 7.77 | Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress. ( Bir, SC; Branch, BG; Greber, E; Kevil, CG; Pardue, S; Patel, RP; Pattillo, CB; Shen, X, 2011) |
| "Dipyridamole preconditioning protects against ischemia/reperfusion injury of the liver." | 7.73 | [Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver]. ( Hong, Y; Liao, WS; Mo, RX, 2006) |
| "We demonstrated marked hepatoprotective effects of dipyridamole against severe ischemia and reperfusion injury in canine livers." | 7.72 | Dipyridamole protects the liver against warm ischemia and reperfusion injury. ( Furukawa, H; Iida, J; Jin, MB; Magata, S; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S, 2004) |
| "To compare the sensitivity of dipyridamole, dobutamine and pacing stress echocardiography for the detection of myocardial ischemia we produced a physiologically significant stenosis in the left circumflex artery of 14 open-chest dogs (range: 50 to 89% reduction in luminal diameter)." | 7.71 | Head-to-head comparison of dipyridamole, dobutamine and pacing stress echocardiography for the detection of myocardial ischemia in an animal model of coronary artery stenosis. ( Ayres-Neto, EM; Carneiro, JJ; de Almeida-Filho, OC; Maciel, BC; Marin-Neto, JA; Schmidt, A, 2001) |
| "This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis." | 7.71 | Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. ( Fang, CC; Hsieh, BS; Hung, KY; Lee, PH; Shyu, RS; Tsai, CC; Tsai, TJ, 2001) |
| "Effect of adenosinergic agents were investigated in lithium-pilocarpine-induced status epilepticus (SE) in rats." | 7.69 | Modulation of lithium-pilocarpine-induced status epilepticus by adenosinergic agents. ( George, B; Kulkarni, SK, 1997) |
| "An experimental model of angina pectoris has been developed in order to study the hemodynamic, metabolic and electrophysiological alterations of the heart assumed to occur in the human disease and to analyze the influence of nitroglycerin and dipyridamole on the above changes." | 7.65 | Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. ( Csik, V; Szekeres, L; Udvary, E, 1976) |
| "Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator." | 6.46 | Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010) |
| "Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity." | 5.43 | Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016) |
| "Hemorrhagic shock is a leading cause of death despite the improvement in emergency services." | 5.38 | Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage. ( Arafah, MM; Soliman, MM, 2012) |
| "Stable pulmonary hypertension was evoked by continuous infusion of the thromboxane mimetic U46619, resulting in approximate doubling of the pulmonary artery pressure (PAP)." | 5.31 | Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. ( Enke, B; Forssmann, WG; Ghofrani, HA; Grimminger, F; Schermuly, RT; Seeger, W; Walmrath, D; Weissmann, N, 2001) |
| "Experimental disseminated intravascular coagulation (DIC) can be induced by 4-h sustained infusion of endotoxin in a dose of 100 mg/kg in rats." | 5.27 | Effect of dipyridamole on experimental disseminated intravascular coagulation in rats. ( Furukawa, Y; Kondo, M; Murakami, M; Takemura, S; Yoshikawa, T, 1983) |
| " Dipyridamole (DPY) is an alternative to counteract the pathophysiological phenomena involved in Chagas cardiomyopathy." | 3.85 | Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis. ( Alvarez, C; Bonfante-Cabarcas, R; Bonfante-Rodríguez, R; Caicedo, P; Giraldo, E; Rodríguez-Bonfante, C; Santeliz, S; Yustiz, MD, 2017) |
| "Our findings show that the use of dipyridamole before testicular reperfusion has a potentially protective effect against long-term injury in testicular ischemia reperfusion injury." | 3.78 | Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury. ( Karagüzel, E; Kazaz, İO; Kutlu, Ö; Mungan, S; Özgür, GK; Tok, DS; Yuluğ, E, 2012) |
| "Dipyridamole anti-platelet therapy has previously been suggested to ameliorate chronic tissue ischemia in healthy animals." | 3.77 | Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress. ( Bir, SC; Branch, BG; Greber, E; Kevil, CG; Pardue, S; Patel, RP; Pattillo, CB; Shen, X, 2011) |
| "Twenty-one beagles and small mongrel dogs without coronary artery stenosis (controls) or with moderate to severe acute coronary artery stenosis underwent MRI and PET imaging at rest and during dipyridamole vasodilation or dobutamine stress to induce a wide range of changes in cardiac perfusion and oxygenation." | 3.76 | Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography. ( Abendschein, DR; Goldstein, TA; Gropler, RJ; Herrero, P; McCommis, KS; Misselwitz, B; Zheng, J, 2010) |
| "Eight mongrel dogs with moderate coronary artery stenosis underwent BOLD imaging at rest and during dipyridamole-induced hyperemia, using a turbo spin echo (TSE) sequence." | 3.74 | Assessment of myocardial oxygen extraction fraction and perfusion reserve with BOLD imaging in a canine model with coronary artery stenosis. ( Gropler, RJ; Li, D; Zhang, H; Zheng, J, 2007) |
| "Using a rat model of cerebral ischemia, the ENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR) significantly increased post-ischemic forebrain adenosine levels and significantly decreased hippocampal neuron injury relative to saline-treatment." | 3.73 | Astrocytes and neurons: different roles in regulating adenosine levels. ( Parkinson, FE; Xiong, W; Zamzow, CR, 2005) |
| "Dipyridamole preconditioning protects against ischemia/reperfusion injury of the liver." | 3.73 | [Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver]. ( Hong, Y; Liao, WS; Mo, RX, 2006) |
| "We demonstrated marked hepatoprotective effects of dipyridamole against severe ischemia and reperfusion injury in canine livers." | 3.72 | Dipyridamole protects the liver against warm ischemia and reperfusion injury. ( Furukawa, H; Iida, J; Jin, MB; Magata, S; Shimamura, T; Suzuki, T; Taniguchi, M; Todo, S, 2004) |
| "To compare the sensitivity of dipyridamole, dobutamine and pacing stress echocardiography for the detection of myocardial ischemia we produced a physiologically significant stenosis in the left circumflex artery of 14 open-chest dogs (range: 50 to 89% reduction in luminal diameter)." | 3.71 | Head-to-head comparison of dipyridamole, dobutamine and pacing stress echocardiography for the detection of myocardial ischemia in an animal model of coronary artery stenosis. ( Ayres-Neto, EM; Carneiro, JJ; de Almeida-Filho, OC; Maciel, BC; Marin-Neto, JA; Schmidt, A, 2001) |
| "This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis." | 3.71 | Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo. ( Fang, CC; Hsieh, BS; Hung, KY; Lee, PH; Shyu, RS; Tsai, CC; Tsai, TJ, 2001) |
| "Effect of adenosinergic agents were investigated in lithium-pilocarpine-induced status epilepticus (SE) in rats." | 3.69 | Modulation of lithium-pilocarpine-induced status epilepticus by adenosinergic agents. ( George, B; Kulkarni, SK, 1997) |
| "An experimental model of angina pectoris has been developed in order to study the hemodynamic, metabolic and electrophysiological alterations of the heart assumed to occur in the human disease and to analyze the influence of nitroglycerin and dipyridamole on the above changes." | 3.65 | Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. ( Csik, V; Szekeres, L; Udvary, E, 1976) |
| "Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator." | 2.46 | Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010) |
| "Dipyridamole (DP) is a phosphodiesterase inhibitor that increases the intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP) by preventing their conversion to AMP and GMP, respectively." | 2.44 | Translational therapeutics of dipyridamole. ( Kim, HH; Liao, JK, 2008) |
| "Dipyridamole is an adenosine receptor indirect agonist with known osteogenic potential." | 1.51 | Regeneration of a Pediatric Alveolar Cleft Model Using Three-Dimensionally Printed Bioceramic Scaffolds and Osteogenic Agents: Comparison of Dipyridamole and rhBMP-2. ( Bekisz, JM; Coelho, PG; Cronstein, BN; Cuadrado, DL; Flores, RL; Greenberg, MI; Guarino, AM; Lopez, CD; Torroni, A; Witek, L, 2019) |
| "Dipyridamole pretreatment in gentamicin-administered rats afforded a noticeable renoprotection by markedly preventing renal structural and functional abnormalities, renal inflammation and serum uric acid elevation." | 1.46 | Effects of pre and post-treatments with dipyridamole in gentamicin-induced acute nephrotoxicity in the rat. ( Bahari, MB; Balakumar, P; Gan, YS; Jayachristy, SA; JemayPuah, SM; Kuganesswari, S; Prajapati, SK; Sundram, K; Varatharajan, R; WitnessKoe, WE, 2017) |
| "Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity." | 1.43 | Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016) |
| "However, AUC(0-3) for DPG/TS under hypochlorhydria was almost identical to that of DPG in normal rats." | 1.38 | Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria. ( Inoue, R; Kawabata, Y; Onoue, S; Taniguchi, C; Wada, K; Yamada, S; Yamashita, K; Yamauchi, Y, 2012) |
| " Pharmacokinetic profiling of orally dosed DPG or DPG with 60% loading of FA (DPG/FA60) was carried out in omeprazole-treated rats as a hypochlorhydric model." | 1.38 | Improved dissolution and pharmacokinetic behavior of dipyridamole formulation with microenvironmental pH-modifier under hypochlorhydria. ( Inoue, R; Kawabata, Y; Onoue, S; Taniguchi, C; Wada, K; Yamada, S; Yamashita, K; Yamauchi, Y, 2012) |
| "Hemorrhagic shock is a leading cause of death despite the improvement in emergency services." | 1.38 | Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage. ( Arafah, MM; Soliman, MM, 2012) |
| "Diet-induced glucose intolerance is associated with impaired myocardial function during conditions of hyperaemia, but myocardial perfusion is maintained." | 1.38 | High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study. ( Boer, C; Bouwman, RA; Bulte, CS; Kloeze, BM; Loer, SA; van den Brom, CE, 2012) |
| "Dipyridamole treatment did not worsen frequency and size of cerebral microscopic bleeding." | 1.37 | Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy. ( Cribbs, DH; Fisher, M; Passos, GF; Quiring, D; Vasilevko, V; Ventura, C, 2011) |
| "Dipyridamole (DP) is a platelet inhibitor with known antithrombotic benefits in stroke prevention." | 1.37 | Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. ( Boada, C; Campos, M; García-Bonilla, L; Hernández-Guillamon, M; Montaner, J; Penalba, A; Rosell, A; Sosti, V; Sumalla, M, 2011) |
| "Only in stunned myocardium (in the setting of single-vessel disease), dipyridamole tends to normalize deformation." | 1.35 | The quantification of dipyridamole induced changes in regional deformation in normal, stunned or infarcted myocardium as measured by strain and strain rate: an experimental study. ( Bijnens, B; Boettler, P; Claus, P; D'hooge, J; Marciniak, A; Marciniak, M; McLaughlin, M; Rademakers, F; Streb, W; Sutherland, GR, 2008) |
| "Dipyridamole was infused (0." | 1.35 | Detection of moderate regional ischemia in pig hearts in vivo by near-infrared and thermal imaging: effects of dipyridamole. ( Kupriyanov, VV; Manley, DM; Xiang, B, 2008) |
| "Stable pulmonary hypertension was evoked by continuous infusion of the thromboxane mimetic U46619, resulting in approximate doubling of the pulmonary artery pressure (PAP)." | 1.31 | Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. ( Enke, B; Forssmann, WG; Ghofrani, HA; Grimminger, F; Schermuly, RT; Seeger, W; Walmrath, D; Weissmann, N, 2001) |
| "However, their effects on thrombus formation have rarely been evaluated in experimental animals in vivo." | 1.29 | In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. ( Iwamoto, Y; Naritomi, H; Nishimura, H; Sugita, M; Tachibana, H, 1996) |
| "Similarly, a pronounced inhibition of thrombus formation was observed by in vivo microscopy and computer-assisted morphometric analysis, after oral treatment of non-anesthetized hamsters with dipyridamole, 5 mg/kg." | 1.28 | Dipyridamole--evaluation of an established antithrombotic drug in view of modern concepts of blood cell-vessel wall interactions. ( Eisert, WG; Müller, TH, 1990) |
| "The mean value of the thrombus area in the dilazep group was 60% smaller and the distribution pattern of the thrombus by size was found to be composed of smaller thrombi than those of the control group." | 1.28 | Thrombus formation on the aorta injured by angioplasty and its prevention with dilazep in atherosclerotic rabbits. ( Asanuma, A; Fujii, M; Nobuyoshi, M; Takimoto, M; Tanaka, M, 1989) |
| "When the mural thrombus was removed from 14 grafts, a median 73% of the platelets were located in the interface between thrombus and graft." | 1.27 | Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. ( Chesebro, JH; Dewanjee, MK; Fuster, V; Kaye, MP; Pumphrey, CW; Vlietstra, RE, 1983) |
| "Experimental disseminated intravascular coagulation (DIC) can be induced by 4-h sustained infusion of endotoxin in a dose of 100 mg/kg in rats." | 1.27 | Effect of dipyridamole on experimental disseminated intravascular coagulation in rats. ( Furukawa, Y; Kondo, M; Murakami, M; Takemura, S; Yoshikawa, T, 1983) |
| "Cardiac hypertrophy is associated with a decrease in coronary reserve." | 1.26 | Effects of duration and severity of arterial hypertension and cardiac hypertrophy on coronary vasodilator reserve. ( Marcus, ML; Peters, KG; Tomanek, RJ; Wangler, RD, 1982) |
| "Trapidil was expected to be an effective antithrombotic agent." | 1.26 | Antithrombotic activity and the mechanism of action of trapidil (Rocornal). ( Kitamura, Y; Ohnishi, H; Shimada, S; Suzuki, Y; Yamaguchi, K, 1982) |
| "Aspirin treatment however may be a precipitating factor when associated with other abnormalities of platelet function." | 1.26 | Bleeding time in rats: a comparison of different experimental conditions. ( de Gaetano, G; Dejana, E; Villa, S, 1982) |
| "Heparin reduced thrombus only when sufficient was given to reduce blood coagulation." | 1.26 | Effects of heparin, aspirin and dipyridamole on thrombus formation on venous catheters. ( Hecker, JF; Spanos, HG, 1979) |
| "Dipyridamole treatment of rabbits caused significant inhibition of fibrin deposition in all three experimental models." | 1.25 | Inhibition of intravascular fibrin deposition by dipyridamole in experimental animals. ( Gurewich, V; Lipinski, B; Wetmore, R, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 42 (36.84) | 18.7374 |
| 1990's | 18 (15.79) | 18.2507 |
| 2000's | 20 (17.54) | 29.6817 |
| 2010's | 30 (26.32) | 24.3611 |
| 2020's | 4 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Evdokiou, A | 1 |
| Marciano-Cabral, F | 1 |
| Jamerson, M | 1 |
| Wang, MM | 1 |
| Flores, RL | 4 |
| Witek, L | 4 |
| Torroni, A | 4 |
| Ibrahim, A | 1 |
| Wang, Z | 1 |
| Liss, HA | 1 |
| Cronstein, BN | 4 |
| Lopez, CD | 4 |
| Maliha, SG | 2 |
| Coelho, PG | 4 |
| Cox, M | 1 |
| Meskin, A | 1 |
| Rusi, S | 1 |
| Oprişoreanu, AM | 1 |
| Smith, HL | 1 |
| Krix, S | 1 |
| Chaytow, H | 1 |
| Carragher, NO | 1 |
| Gillingwater, TH | 1 |
| Becker, CG | 1 |
| Becker, T | 1 |
| Matyash, M | 1 |
| Zabiegalov, O | 1 |
| Wendt, S | 1 |
| Matyash, V | 1 |
| Kettenmann, H | 1 |
| Santeliz, S | 1 |
| Caicedo, P | 1 |
| Giraldo, E | 1 |
| Alvarez, C | 1 |
| Yustiz, MD | 1 |
| Rodríguez-Bonfante, C | 1 |
| Bonfante-Rodríguez, R | 1 |
| Bonfante-Cabarcas, R | 1 |
| Amtul, Z | 1 |
| Haque, W | 1 |
| Cechetto, DF | 1 |
| Tanaka, DM | 1 |
| de Oliveira, LFL | 1 |
| Marin-Neto, JA | 2 |
| Romano, MMD | 1 |
| de Carvalho, EEV | 1 |
| de Barros Filho, ACL | 1 |
| Ribeiro, FFF | 1 |
| Cabeza, JM | 1 |
| Lopes, CD | 1 |
| Fabricio, CG | 1 |
| Kesper, N | 1 |
| Moreira, HT | 1 |
| Wichert-Ana, L | 1 |
| Schmidt, A | 2 |
| Higuchi, ML | 1 |
| Cunha-Neto, E | 1 |
| Simões, MV | 1 |
| Do, HP | 1 |
| Ramanan, V | 1 |
| Qi, X | 1 |
| Barry, J | 1 |
| Wright, GA | 1 |
| Ghugre, NR | 1 |
| Nayak, KS | 1 |
| Ali, RA | 1 |
| Gandhi, AA | 1 |
| Meng, H | 1 |
| Yalavarthi, S | 1 |
| Vreede, AP | 1 |
| Estes, SK | 1 |
| Palmer, OR | 1 |
| Bockenstedt, PL | 1 |
| Pinsky, DJ | 1 |
| Greve, JM | 1 |
| Diaz, JA | 1 |
| Kanthi, Y | 1 |
| Knight, JS | 1 |
| Diaz-Siso, JR | 1 |
| Bekisz, JM | 2 |
| Gil, LF | 1 |
| Rodriguez, ED | 1 |
| Greenberg, MI | 1 |
| Cuadrado, DL | 1 |
| Guarino, AM | 1 |
| Liu, Y | 2 |
| Oh, SJ | 1 |
| Chang, KH | 1 |
| Kim, YG | 1 |
| Lee, MY | 1 |
| Bortolotto, JW | 1 |
| Melo, GM | 1 |
| Cognato, Gde P | 1 |
| Vianna, MR | 1 |
| Bonan, CD | 1 |
| Cabiati, M | 1 |
| Burchielli, S | 1 |
| Matteucci, M | 1 |
| Svezia, B | 1 |
| Panchetti, L | 1 |
| Caselli, C | 1 |
| Prescimone, T | 1 |
| Morales, MA | 1 |
| Del Ry, S | 1 |
| Puri, N | 1 |
| Mohey, V | 1 |
| Singh, M | 1 |
| Kaur, T | 1 |
| Pathak, D | 1 |
| Buttar, HS | 1 |
| Singh, AP | 1 |
| Cappato, S | 1 |
| Tonachini, L | 1 |
| Giacopelli, F | 1 |
| Tirone, M | 1 |
| Galietta, LJ | 1 |
| Sormani, M | 1 |
| Giovenzana, A | 1 |
| Spinelli, AE | 1 |
| Canciani, B | 1 |
| Brunelli, S | 1 |
| Ravazzolo, R | 1 |
| Bocciardi, R | 1 |
| Balakumar, P | 1 |
| WitnessKoe, WE | 1 |
| Gan, YS | 1 |
| JemayPuah, SM | 1 |
| Kuganesswari, S | 1 |
| Prajapati, SK | 1 |
| Varatharajan, R | 1 |
| Jayachristy, SA | 1 |
| Sundram, K | 1 |
| Bahari, MB | 1 |
| Guitart, X | 1 |
| Chern, Y | 1 |
| Ferré, S | 1 |
| McCommis, KS | 2 |
| Zhang, H | 2 |
| Goldstein, TA | 2 |
| Misselwitz, B | 2 |
| Abendschein, DR | 2 |
| Gropler, RJ | 3 |
| Zheng, J | 3 |
| Herrero, P | 1 |
| d'Esterre, CD | 1 |
| Lee, TY | 1 |
| Melani, A | 1 |
| Cipriani, S | 1 |
| Corti, F | 1 |
| Pedata, F | 1 |
| Pattillo, CB | 1 |
| Bir, SC | 1 |
| Branch, BG | 1 |
| Greber, E | 1 |
| Shen, X | 1 |
| Pardue, S | 1 |
| Patel, RP | 1 |
| Kevil, CG | 1 |
| García-Bonilla, L | 1 |
| Sosti, V | 1 |
| Campos, M | 1 |
| Penalba, A | 1 |
| Boada, C | 1 |
| Sumalla, M | 1 |
| Hernández-Guillamon, M | 1 |
| Rosell, A | 1 |
| Montaner, J | 1 |
| Nihoyannopoulos, P | 1 |
| Vanoverschelde, JL | 1 |
| van Giezen, JJ | 1 |
| Sidaway, J | 1 |
| Glaves, P | 1 |
| Kirk, I | 1 |
| Björkman, JA | 1 |
| Fisher, M | 1 |
| Vasilevko, V | 1 |
| Passos, GF | 1 |
| Ventura, C | 1 |
| Quiring, D | 1 |
| Cribbs, DH | 1 |
| Soliman, MM | 1 |
| Arafah, MM | 1 |
| Onoue, S | 2 |
| Inoue, R | 2 |
| Taniguchi, C | 2 |
| Kawabata, Y | 2 |
| Yamashita, K | 2 |
| Wada, K | 2 |
| Yamauchi, Y | 2 |
| Yamada, S | 2 |
| van den Brom, CE | 1 |
| Bulte, CS | 1 |
| Kloeze, BM | 1 |
| Loer, SA | 1 |
| Boer, C | 1 |
| Bouwman, RA | 1 |
| Karagüzel, E | 1 |
| Kutlu, Ö | 1 |
| Yuluğ, E | 1 |
| Mungan, S | 1 |
| Kazaz, İO | 1 |
| Tok, DS | 1 |
| Özgür, GK | 1 |
| Hewitson, TD | 1 |
| Tait, MG | 1 |
| Kelynack, KJ | 1 |
| Martic, M | 1 |
| Becker, GJ | 1 |
| Kosieradzki, M | 1 |
| Ametani, M | 1 |
| Southard, JH | 1 |
| Mangino, MJ | 1 |
| Taniguchi, M | 1 |
| Magata, S | 1 |
| Suzuki, T | 1 |
| Shimamura, T | 1 |
| Jin, MB | 1 |
| Iida, J | 1 |
| Furukawa, H | 1 |
| Todo, S | 1 |
| Fleming, JS | 1 |
| Buyniski, JP | 1 |
| Parkinson, FE | 1 |
| Xiong, W | 1 |
| Zamzow, CR | 1 |
| Li, H | 1 |
| Cone, J | 1 |
| Fong, M | 1 |
| Kambayashi, J | 1 |
| Yoshitake, M | 1 |
| Kuji, T | 1 |
| Masaki, T | 1 |
| Goteti, K | 1 |
| Li, L | 1 |
| Zhuplatov, S | 1 |
| Terry, CM | 1 |
| Zhu, W | 1 |
| Leypoldt, JK | 1 |
| Rathi, R | 1 |
| Blumenthal, DK | 1 |
| Kern, SE | 1 |
| Cheung, AK | 1 |
| Hong, Y | 1 |
| Liao, WS | 1 |
| Mo, RX | 1 |
| Kupriyanov, VV | 1 |
| Manley, DM | 1 |
| Xiang, B | 1 |
| Li, D | 1 |
| Marciniak, M | 1 |
| Claus, P | 1 |
| Streb, W | 1 |
| Marciniak, A | 1 |
| Boettler, P | 1 |
| McLaughlin, M | 1 |
| D'hooge, J | 1 |
| Rademakers, F | 1 |
| Bijnens, B | 1 |
| Sutherland, GR | 1 |
| Kim, HH | 1 |
| Liao, JK | 1 |
| Carneiro, FS | 1 |
| Giachini, FRC | 1 |
| Lima, VV | 1 |
| Carneiro, ZN | 1 |
| Leite, R | 1 |
| Inscho, EW | 1 |
| Tostes, RC | 1 |
| Webb, RC | 1 |
| Weichert, W | 2 |
| Pauliks, V | 1 |
| Breddin, HK | 2 |
| Wangler, RD | 1 |
| Peters, KG | 1 |
| Marcus, ML | 1 |
| Tomanek, RJ | 1 |
| Suzuki, Y | 1 |
| Yamaguchi, K | 1 |
| Shimada, S | 1 |
| Kitamura, Y | 1 |
| Ohnishi, H | 1 |
| Rothendler, JA | 1 |
| Okada, RD | 4 |
| Strauss, HW | 1 |
| Chesler, DA | 1 |
| Pohost, GM | 2 |
| Rozonov, IuB | 1 |
| Morozova, TV | 1 |
| Dejana, E | 1 |
| Villa, S | 1 |
| de Gaetano, G | 1 |
| Pumphrey, CW | 1 |
| Fuster, V | 1 |
| Dewanjee, MK | 1 |
| Chesebro, JH | 1 |
| Vlietstra, RE | 1 |
| Kaye, MP | 1 |
| Yoshikawa, T | 1 |
| Murakami, M | 1 |
| Furukawa, Y | 1 |
| Takemura, S | 1 |
| Kondo, M | 1 |
| Leppo, JA | 1 |
| Boucher, CA | 1 |
| Rao, PS | 1 |
| Cavanagh, D | 1 |
| Gaston, LW | 1 |
| Sakai, K | 1 |
| Akima, M | 1 |
| Aono, J | 1 |
| Cousineau, DF | 1 |
| Goresky, CA | 1 |
| Rose, CP | 1 |
| Simard, A | 1 |
| Schwab, AJ | 1 |
| Johnson, G | 1 |
| Glover, DK | 1 |
| Hebert, CB | 1 |
| Gewirtz, H | 1 |
| Bullough, DA | 1 |
| Zhang, C | 1 |
| Montag, A | 1 |
| Mullane, KM | 1 |
| Young, MA | 1 |
| Villanueva, FS | 1 |
| Glasheen, WP | 1 |
| Sklenar, J | 1 |
| Kaul, S | 1 |
| Isono, T | 1 |
| Sato, N | 1 |
| Koibuchi, Y | 1 |
| Sakai, S | 1 |
| Yamamoto, T | 1 |
| Ozaki, R | 1 |
| Mori, J | 1 |
| Kohsaka, M | 1 |
| Ohtsuka, M | 1 |
| Nishimura, H | 1 |
| Naritomi, H | 1 |
| Iwamoto, Y | 1 |
| Tachibana, H | 1 |
| Sugita, M | 1 |
| Hay, KA | 1 |
| Gaydos, A | 1 |
| Tenser, RB | 1 |
| George, B | 1 |
| Kulkarni, SK | 1 |
| Hanson, KA | 1 |
| Ziegler, JW | 1 |
| Rybalkin, SD | 1 |
| Miller, JW | 1 |
| Abman, SH | 1 |
| Clarke, WR | 1 |
| Dukarm, RC | 1 |
| Morin, FC | 1 |
| Russell, JA | 1 |
| Steinhorn, RH | 1 |
| Shishido, T | 1 |
| Beppu, S | 1 |
| Matsuda, H | 1 |
| Miyatake, K | 1 |
| Thébaud, B | 1 |
| de Lagausie, P | 1 |
| Forgues, D | 1 |
| Aigrain, Y | 1 |
| Mercier, JC | 1 |
| Dinh-Xuan, AT | 1 |
| Olinde, JG | 1 |
| Zibari, GB | 1 |
| Brown, MF | 1 |
| Howell, JG | 1 |
| Akgür, FM | 1 |
| Granger, DN | 1 |
| McDonald, JC | 1 |
| Bin, J | 1 |
| Wei, K | 1 |
| Pelberg, RA | 1 |
| Smart, T | 1 |
| Hung, KY | 1 |
| Shyu, RS | 1 |
| Fang, CC | 1 |
| Tsai, CC | 1 |
| Lee, PH | 1 |
| Tsai, TJ | 1 |
| Hsieh, BS | 1 |
| de Almeida-Filho, OC | 1 |
| Ayres-Neto, EM | 1 |
| Carneiro, JJ | 1 |
| Maciel, BC | 1 |
| Schermuly, RT | 1 |
| Weissmann, N | 1 |
| Enke, B | 1 |
| Ghofrani, HA | 1 |
| Forssmann, WG | 1 |
| Grimminger, F | 1 |
| Seeger, W | 1 |
| Walmrath, D | 1 |
| Cheng, JT | 1 |
| Chi, TC | 1 |
| Liu, IM | 1 |
| Zitowitz, L | 1 |
| Stimson, J | 1 |
| Wohl, AJ | 1 |
| Ehrreich, SJ | 1 |
| Bream, ML | 1 |
| Philp, RB | 1 |
| Ferguson, GG | 1 |
| Lee, RJ | 1 |
| Baky, SH | 1 |
| Harker, LA | 2 |
| Hanson, SR | 1 |
| Blass, KE | 1 |
| Triebe, G | 1 |
| Traub, F | 1 |
| Förster, W | 1 |
| Friedman, RJ | 1 |
| Burns, ER | 1 |
| Spanos, HG | 1 |
| Hecker, JF | 1 |
| Rossi, EC | 1 |
| Szekeres, L | 1 |
| Csik, V | 1 |
| Udvary, E | 1 |
| Bolanowski, PJ | 1 |
| Bauer, J | 1 |
| Machiedo, G | 1 |
| Neville, WE | 1 |
| Gurewich, V | 2 |
| Lipinski, B | 2 |
| Wetmore, R | 1 |
| Lavelle, SM | 1 |
| MacIomhair, M | 1 |
| Sumida, S | 1 |
| Faxon, DP | 1 |
| Balelli, LA | 1 |
| Sandborn, T | 1 |
| Haudenschild, C | 1 |
| Valeri, R | 1 |
| Ryan, TJ | 1 |
| De La Cruz, JP | 1 |
| Villalobos, MA | 1 |
| Carrasco, T | 1 |
| Smith-Agreda, JM | 1 |
| Sánchez de la Cuesta, F | 1 |
| Mousa, SA | 1 |
| Cooney, JM | 1 |
| Keane, TE | 1 |
| Rosner, GL | 1 |
| Gingrich, JR | 1 |
| Poulton, SH | 1 |
| Walther, PJ | 1 |
| Eisert, WG | 1 |
| Müller, TH | 1 |
| Nobuyoshi, M | 1 |
| Tanaka, M | 1 |
| Fujii, M | 1 |
| Asanuma, A | 1 |
| Takimoto, M | 1 |
| Cheirif, J | 1 |
| Zoghbi, WA | 1 |
| Bolli, R | 1 |
| O'Neill, PG | 1 |
| Hoyt, BD | 1 |
| Quinones, MA | 1 |
| Miller, DD | 1 |
| Holmvang, G | 1 |
| Gill, JB | 1 |
| Dragotakes, D | 1 |
| Kantor, HL | 1 |
| Brady, TJ | 1 |
| Hladovec, J | 2 |
| Lane, IF | 1 |
| Irwin, JT | 1 |
| Jennings, SA | 1 |
| Poskitt, KR | 1 |
| Meek, AC | 1 |
| McCollum, CN | 1 |
| Lima, JA | 1 |
| Becker, LC | 1 |
| Melin, JA | 1 |
| Lima, S | 1 |
| Kallman, CA | 1 |
| Weisfeldt, ML | 1 |
| Weiss, JL | 1 |
| Slichter, SJ | 1 |
| Scott, CR | 1 |
| Ross, R | 1 |
| Loew, D | 1 |
| Williams, IM | 1 |
| Farmer, S | 1 |
| Dixon, J | 1 |
| Dragojevic, D | 1 |
| Hetzer, R | 1 |
| Corterier, H | 1 |
| Mayer, JE | 1 |
| Hammond, GL | 1 |
| Kobayakawa, T | 1 |
| Jones, CE | 1 |
| Bethea, HL | 1 |
| Smith, EE | 1 |
| Crowell, JW | 1 |
| Byrne, JJ | 1 |
| Migliore, JJ | 1 |
| Beekley, W | 1 |
| Guardione, VA | 1 |
| Williams, LF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Non-invasive Evaluation of Cerebrovascular Reactivity in Spontaneous Intracerebral Hemorrhage[NCT03815513] | Phase 1 | 60 participants (Anticipated) | Interventional | 2019-01-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for dipyridamole and Disease Models, Animal
| Article | Year |
|---|---|
Effect of dipyridamole during acute stroke: exploring antithrombosis and neuroprotective benefits.
Topics: Animals; Cerebrovascular Circulation; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Hum | 2010 |
Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.
Topics: Animals; Brain Ischemia; Carotid Artery, Common; Dipyridamole; Disease Models, Animal; Humans; Infus | 2010 |
Translational therapeutics of dipyridamole.
Topics: Acute Coronary Syndrome; Animals; Cyclic AMP; Cyclic GMP; Dipyridamole; Disease Models, Animal; Endo | 2008 |
Role of platelets in the proliferative response of the injured artery.
Topics: Animals; Arteries; Arteriosclerosis; Blood Platelets; Cell Differentiation; Cell Survival; Dipyridam | 1978 |
[The importance of thrombocytes for thrombogenesis and the pharmacological influencing of thrombocyte function (author's transl)].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelet Disorders; Blood Platelets; Clinical Trials as Topi | 1974 |
1 trial available for dipyridamole and Disease Models, Animal
| Article | Year |
|---|---|
[The importance of thrombocytes for thrombogenesis and the pharmacological influencing of thrombocyte function (author's transl)].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelet Disorders; Blood Platelets; Clinical Trials as Topi | 1974 |
109 other studies available for dipyridamole and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Studies on the cyst stage of Naegleria fowleri in vivo and in vitro.
Topics: Amebiasis; Animals; Central Nervous System Protozoal Infections; Cysts; Dipyridamole; Disease Models | 2022 |
Dipyridamole-loaded 3D-printed bioceramic scaffolds stimulate pediatric bone regeneration in vivo without disruption of craniofacial growth through facial maturity.
Topics: Animals; Bioprinting; Bone Regeneration; Calcium Phosphates; Ceramics; Child; Child Development; Dip | 2019 |
Bone Tissue Engineering in the Growing Calvaria Using Dipyridamole-Coated, Three-Dimensionally-Printed Bioceramic Scaffolds: Construct Optimization and Effects on Cranial Suture Patency.
Topics: Animals; Bone Regeneration; Calcium Phosphates; Dipyridamole; Disease Models, Animal; Rabbits; Skull | 2020 |
Automated in vivo drug screen in zebrafish identifies synapse-stabilising drugs with relevance to spinal muscular atrophy.
Topics: Animals; Automation; Axons; Dipyridamole; Disease Models, Animal; Drug Evaluation, Preclinical; Gene | 2021 |
The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Animals; Animals, Newborn; Antigens, CD; Apyrase | 2017 |
Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis.
Topics: Acute Disease; Animals; Chagas Cardiomyopathy; Dipyridamole; Disease Models, Animal; Drug Synergism; | 2017 |
Dipyridamole plus Triflusal versus Triflusal Alone in Infarct Reduction after Middle Cerebral Artery Occlusion.
Topics: Animals; Brain; Cytoprotection; Dipyridamole; Disease Models, Animal; Dose-Response Relationship, Dr | 2018 |
Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy.
Topics: Animals; Chagas Cardiomyopathy; Cricetinae; Dipyridamole; Disease Models, Animal; Echocardiography; | 2019 |
Non-contrast assessment of microvascular integrity using arterial spin labeled cardiovascular magnetic resonance in a porcine model of acute myocardial infarction.
Topics: Animals; Coronary Circulation; Coronary Vessels; Dipyridamole; Disease Models, Animal; Feasibility S | 2018 |
Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Antibodies, Antiphospholipid; Antiphospholipid S | 2019 |
Dipyridamole Augments Three-Dimensionally Printed Bioactive Ceramic Scaffolds to Regenerate Craniofacial Bone.
Topics: Adenosine A2 Receptor Agonists; Animals; Bone Regeneration; Ceramics; Collagen; Dipyridamole; Diseas | 2019 |
Regeneration of a Pediatric Alveolar Cleft Model Using Three-Dimensionally Printed Bioceramic Scaffolds and Osteogenic Agents: Comparison of Dipyridamole and rhBMP-2.
Topics: Alveolar Process; Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 2; Bone Rege | 2019 |
Antiplatelet effect of AMP-activated protein kinase activator and its potentiation by the phosphodiesterase inhibitor dipyridamole.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Cyclic GMP; Dipyridamole; Diseas | 2013 |
Modulation of adenosine signaling prevents scopolamine-induced cognitive impairment in zebrafish.
Topics: Adenine; Adenosine; Adenosine Deaminase Inhibitors; Animals; Avoidance Learning; Cognition Disorders | 2015 |
Dipyridamole-induced C-type natriuretic peptide mRNA overexpression in a minipig model of pacing-induced left ventricular dysfunction.
Topics: Animals; Cardiac Pacing, Artificial; Dipyridamole; Disease Models, Animal; Heart; Natriuretic Peptid | 2015 |
Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats.
Topics: Acute Kidney Injury; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 | 2016 |
High-throughput screening for modulators of ACVR1 transcription: discovery of potential therapeutics for fibrodysplasia ossificans progressiva.
Topics: Activin Receptors, Type I; Animals; Biomarkers; Bone Morphogenetic Proteins; Calcium; Cell Different | 2016 |
Effects of pre and post-treatments with dipyridamole in gentamicin-induced acute nephrotoxicity in the rat.
Topics: Animals; Anti-Inflammatory Agents; Biomarkers; Creatinine; Cytoprotection; Dipyridamole; Disease Mod | 2017 |
Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.
Topics: Age of Onset; Animals; Animals, Genetically Modified; Biomarkers; Brain; Carrier Proteins; Corpus St | 2017 |
Myocardial blood volume is associated with myocardial oxygen consumption: an experimental study with cardiac magnetic resonance in a canine model.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Stenosis; Dipyridamole; Disease Models, Anim | 2009 |
Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography.
Topics: Acute Disease; Adrenergic beta-Agonists; Animals; Carbon Radioisotopes; Coronary Circulation; Corona | 2010 |
Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress.
Topics: Animals; Diabetes Mellitus, Experimental; Dipyridamole; Disease Models, Animal; Hindlimb; Hyperchole | 2011 |
Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia.
Topics: Animals; Aquaporins; Brain; Brain Infarction; Chemokine CCL2; Dipyridamole; Disease Models, Animal; | 2011 |
Myocardial ischaemia and viability: the pivotal role of echocardiography.
Topics: Animals; Cardiotonic Agents; Contrast Media; Coronary Circulation; Diagnosis, Differential; Dipyrida | 2011 |
Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cell Line; Cell Line, Tumor; Coronary Circulation; Dipy | 2012 |
Therapeutic modulation of cerebral microhemorrhage in a mouse model of cerebral amyloid angiopathy.
Topics: Animals; Cerebral Amyloid Angiopathy; Cerebral Hemorrhage; Dipyridamole; Disease Models, Animal; Fem | 2011 |
Treatment with dipyridamole improves cardiac function and prevent injury in a rat model of hemorrhage.
Topics: Animals; Blood Pressure; Dipyridamole; Disease Models, Animal; Heart; Hemorrhage; Hydrogen-Ion Conce | 2012 |
Improved dissolution and pharmacokinetic behavior of dipyridamole formulation with microenvironmental pH-modifier under hypochlorhydria.
Topics: Achlorhydria; Administration, Oral; Animals; Area Under Curve; Biological Availability; Chemistry, P | 2012 |
Novel formulations of dipyridamole with microenvironmental pH-modifiers for improved dissolution and bioavailability under hypochlorhydria.
Topics: Achlorhydria; Administration, Oral; Animals; Area Under Curve; Benzenesulfonates; Biological Availab | 2012 |
High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study.
Topics: Animals; Coronary Circulation; Diet, High-Fat; Dipyridamole; Disease Models, Animal; Glucose Intoler | 2012 |
Comparison of the protective effect of dipyridamole and acetylsalicylic acid on long-term histologic damage in a rat model of testicular ischemia-reperfusion injury.
Topics: Animals; Apoptosis; Aspirin; Dipyridamole; Disease Models, Animal; Drug Administration Schedule; In | 2012 |
Dipyridamole inhibits in vitro renal fibroblast proliferation and collagen synthesis.
Topics: Animals; Cell Division; Cell Survival; Cells, Cultured; Collagen; Dipyridamole; Disease Models, Anim | 2002 |
Is ischemic preconditioning of the kidney clinically relevant?
Topics: Animals; Cold Temperature; Dipyridamole; Disease Models, Animal; Dogs; Glomerular Filtration Rate; H | 2003 |
Dipyridamole protects the liver against warm ischemia and reperfusion injury.
Topics: Animals; Blood Pressure; Cyclic AMP; Dipyridamole; Disease Models, Animal; Dogs; Energy Metabolism; | 2004 |
Enhanced platelet aggregability in dogs following myocardial infarction.
Topics: Animals; Blood Platelets; Carrier Proteins; Collagen; Coronary Vessels; Dipyridamole; Disease Models | 1977 |
Astrocytes and neurons: different roles in regulating adenosine levels.
Topics: Adenosine; Affinity Labels; Animals; Astrocytes; Brain Ischemia; Cells, Cultured; Deoxyglucose; Dipy | 2005 |
Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation.
Topics: Animals; Bleeding Time; Carotid Artery Thrombosis; Cilostazol; Dipyridamole; Disease Models, Animal; | 2005 |
Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis.
Topics: Animals; Arteriovenous Shunt, Surgical; Carotid Arteries; Cell Proliferation; Delayed-Action Prepara | 2006 |
[Dipyridamole preconditioning protects against ischemia/reperfusion injury of rat liver].
Topics: Animals; Dipyridamole; Disease Models, Animal; Female; Ischemic Preconditioning; Liver; Male; Random | 2006 |
Detection of moderate regional ischemia in pig hearts in vivo by near-infrared and thermal imaging: effects of dipyridamole.
Topics: Animals; Blood Pressure; Body Temperature; Coronary Circulation; Coronary Vessels; Dipyridamole; Dis | 2008 |
Assessment of myocardial oxygen extraction fraction and perfusion reserve with BOLD imaging in a canine model with coronary artery stenosis.
Topics: Animals; Blood Volume; Contrast Media; Coronary Circulation; Coronary Stenosis; Dipyridamole; Diseas | 2007 |
The quantification of dipyridamole induced changes in regional deformation in normal, stunned or infarcted myocardium as measured by strain and strain rate: an experimental study.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Coronary Stenosis; Dipyridamole; Disease Models, | 2008 |
Adenosine actions are preserved in corpus cavernosum from obese and type II diabetic db/db mouse.
Topics: Acetylcholine; Adenosine; Adenosine Kinase; Animals; Diabetes Mellitus, Type 2; Dipyridamole; Diseas | 2008 |
Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs.
Topics: Animals; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Fibrinolytic Agents; Hepari | 1983 |
Effects of duration and severity of arterial hypertension and cardiac hypertrophy on coronary vasodilator reserve.
Topics: Animals; Cardiomegaly; Coronary Circulation; Dipyridamole; Disease Models, Animal; Hypertension; Mal | 1982 |
Antithrombotic activity and the mechanism of action of trapidil (Rocornal).
Topics: Adenosine Triphosphate; Animals; Aspirin; Blood Coagulation; Blood Platelets; Dipyridamole; Disease | 1982 |
Evaluation in dogs of a new double-dose technique for imaging changes in myocardial perfusion.
Topics: Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, Animal; Dogs; Evaluat | 1984 |
[Evaluation of the antianginal action of pharmacological substances by the change in the initiation threshold for myocardial ischemia in conscious rabbits].
Topics: Angina Pectoris; Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, Anim | 1984 |
Bleeding time in rats: a comparison of different experimental conditions.
Topics: Anesthetics; Animals; Aspirin; Bleeding Time; Blood Coagulation; Blood Platelet Disorders; Dipyridam | 1982 |
Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs.
Topics: Animals; Blood Platelets; Calcium Channel Blockers; Dipyridamole; Disease Models, Animal; Dogs; Fibr | 1983 |
Effect of dipyridamole on experimental disseminated intravascular coagulation in rats.
Topics: Animals; Dipyridamole; Disease Models, Animal; Disseminated Intravascular Coagulation; Endotoxins; F | 1983 |
Myocardial kinetics of thallium-201 after dipyridamole infusion in normal canine myocardium and in myocardium distal to a stenosis.
Topics: Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, Animal; Dogs; Hemodyn | 1982 |
Endotoxic shock in the primate: effects of aspirin and dipyridamole administration.
Topics: Animals; Aspirin; Blood Coagulation; Blood Pressure; Depression, Chemical; Dipyridamole; Disease Mod | 1981 |
Evaluation of drug effects in a new experimental model of angina pectoris in the intact anesthetized rat.
Topics: Acetylcholine; Adenosine; Anesthesia; Angina Pectoris; Animals; Coronary Vessels; Diltiazem; Dipyrid | 1981 |
Effects of flow, perfusion pressure, and oxygen consumption on cardiac capillary exchange.
Topics: Animals; Blood Flow Velocity; Blood Gas Analysis; Capillary Permeability; Carotid Stenosis; Coronary | 1995 |
Myocardial clearance kinetics of technetium-99m-teboroxime following dipyridamole: differentiation of stenosis severity in canine myocardium.
Topics: Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, Animal; Dogs; Hemodyn | 1995 |
Myocardial clearance kinetics of technetium-99m-teboroxime following dipyridamole injection.
Topics: Animals; Coronary Disease; Dipyridamole; Disease Models, Animal; Dogs; Humans; Myocardium; Organotec | 1995 |
Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
Topics: Adenosine; Adenosine Deaminase; Adenosine Kinase; Aminoimidazole Carboxamide; Animals; Aspirin; Bloo | 1994 |
Characterization of spatial patterns of flow within the reperfused myocardium by myocardial contrast echocardiography. Implications in determining extent of myocardial salvage.
Topics: Animals; Coronary Circulation; Dipyridamole; Disease Models, Animal; Dogs; Echocardiography; Microsp | 1993 |
Effect of FK409, a novel nitric oxide donor, on acute experimental myocardial ischemia.
Topics: Animals; Coronary Circulation; Coronary Vessels; Dipyridamole; Disease Models, Animal; Dogs; Electri | 1993 |
In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis.
Topics: Animals; Aspirin; Carotid Artery Diseases; Carotid Artery Injuries; Carotid Artery, Common; Cerebrov | 1996 |
Inhibition of herpes simplex virus reactivation by dipyridamole in a mouse model.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Dipyridamole; Disease Models, Animal; Ganglia, Spin | 1996 |
Modulation of lithium-pilocarpine-induced status epilepticus by adenosinergic agents.
Topics: 2-Chloroadenosine; Adenosine; Animals; Anticonvulsants; Carbamazepine; Dipyridamole; Disease Models, | 1997 |
Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Animals, Newborn; Blood Pressure; Chronic Disease; Cyc | 1998 |
Pulmonary and systemic effects of the phosphodiesterase inhibitor dipyridamole in newborn lambs with persistent pulmonary hypertension.
Topics: Animals; Animals, Newborn; Cyclic GMP; Dipyridamole; Disease Models, Animal; Female; Hemodynamics; H | 1998 |
Assessment of flow mismatch with pharmacologic stress test on myocardial contrast echocardiography in a model of critical stenosis: adenosine triphosphate and dipyridamole.
Topics: Adenosine Triphosphate; Albumins; Animals; Blood Pressure; Contrast Media; Coronary Circulation; Cor | 1999 |
ET(A)-receptor blockade and ET(B)-receptor stimulation in experimental congenital diaphragmatic hernia.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Cyclic GMP; Dipyridamole; Disease Models, Animal; E | 2000 |
Persantine attenuates hemorrhagic shock-induced P-selectin expression.
Topics: Adenosine; Animals; Colon; Dipyridamole; Disease Models, Animal; Drug Evaluation, Preclinical; Intes | 2000 |
[Assessment of the effects of dipyridamole and dobutamine on coronary microcirculation using myocardial contrast echocardiography].
Topics: Animals; Blood Flow Velocity; Blood Volume; Coronary Circulation; Coronary Stenosis; Dipyridamole; D | 2000 |
Beyond hydroxyurea.
Topics: Animals; Antiviral Agents; Benzamidines; Dipyridamole; Disease Models, Animal; Floxuridine; Fluorour | 1995 |
Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo.
Topics: Animals; Cell Adhesion; Cell Division; Cells, Cultured; Collagen; Cyclic AMP; Dipyridamole; Disease | 2001 |
Head-to-head comparison of dipyridamole, dobutamine and pacing stress echocardiography for the detection of myocardial ischemia in an animal model of coronary artery stenosis.
Topics: Animals; Cardiac Pacing, Artificial; Cardiotonic Agents; Coronary Disease; Dipyridamole; Disease Mod | 2001 |
Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Administration, Inhalation; Anim | 2001 |
Activation of adenosine A1 receptors by drugs to lower plasma glucose in streptozotocin-induced diabetic rats.
Topics: Adenosine; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Dipyridamole; Disea | 2000 |
Pharmacology of Sch 11973, N-(2-phenylisopropyl)-N-p-toluene sulfonyl urea, a potential new antianginal agent.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Coronary Disease; Dipyridamole; Disease Model | 1977 |
Antiplatelet drugs in a rat microsurgical model of arterial thrombosis.
Topics: Animals; Aspirin; Blood Coagulation; Blood Platelets; Carotid Artery Thrombosis; Dipyridamole; Disea | 1979 |
The isoproterenol stress test in unanesthetized atherosclerotic rabbits.
Topics: Animals; Arteriosclerosis; Coronary Disease; Dipyridamole; Disease Models, Animal; Electrocardiograp | 1978 |
Experimental arterial thromboembolism in baboons. Mechanism, quantitation, and pharmacologic prevention.
Topics: Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Platelets; Blood Transfusion; Dipyridamole; D | 1979 |
Influence of long-term treatment with dipyridamole on the aorta-stenosed rabbit heart: morphometric and functional investigations.
Topics: Animals; Aortic Valve Stenosis; Blood Pressure; Cardiomegaly; Dipyridamole; Disease Models, Animal; | 1976 |
Effects of heparin, aspirin and dipyridamole on thrombus formation on venous catheters.
Topics: Animals; Aspirin; Catheterization; Dipyridamole; Disease Models, Animal; Face; Heparin; Polyethylene | 1979 |
Inhibitors of platelet function and atherogenesis.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Disease Models, Animal; Humans; P | 1979 |
Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris.
Topics: Angina Pectoris; Animals; Blood Pressure; Cardiac Output; Coronary Circulation; Dipyridamole; Diseas | 1976 |
Prostaglandin influence on pulmonary intravascular leukocytic aggregation during cardiopulmonary bypass.
Topics: Animals; Cardiopulmonary Bypass; Cell Aggregation; Dipyridamole; Disease Models, Animal; Dogs; Leuko | 1977 |
Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole.
Topics: Animals; Aspirin; Dipyridamole; Disease Models, Animal; Drug Evaluation, Preclinical; Fibrinolytic A | 1976 |
Inhibition of intravascular fibrin deposition by dipyridamole in experimental animals.
Topics: Aminocaproates; Animals; Autoradiography; Blood Platelets; Dipyridamole; Disease Models, Animal; End | 1975 |
Proceedings: The anti-thrombotic effect of warfarin, dipyridamole and aspirin in the rat.
Topics: Animals; Aspirin; Dipyridamole; Disease Models, Animal; Rats; Thrombosis; Warfarin | 1975 |
A new model to evaluate the thrombus formation due to foreign materials in the great vessels, and the effect of dipyridamole and heparin.
Topics: Animals; Catheterization; Dipyridamole; Disease Models, Animal; Foreign Bodies; Heparin; Male; Pulmo | 1976 |
The effect of antiplatelet therapy on platelet accumulation after experimental angioplasty in the rabbit iliac model.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Dipyridamole; Disease Models, Animal; Drug | 1992 |
The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia reperfusion.
Topics: Animals; Brain; Dipyridamole; Disease Models, Animal; Ischemic Attack, Transient; Lipid Peroxidation | 1992 |
Detection sensitivity of coronary artery stenosis by 99mTc-sestamibi and 201T1 in canine models of partial and subcritical stenosis.
Topics: Animals; Chromium Radioisotopes; Coronary Disease; Dipyridamole; Disease Models, Animal; Dogs; Elect | 1991 |
The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cisplatin; Dipyridamole; Disease | 1991 |
Dipyridamole--evaluation of an established antithrombotic drug in view of modern concepts of blood cell-vessel wall interactions.
Topics: Animals; Blood Vessels; Cholesterol, Dietary; Cricetinae; Dipyridamole; Disease Models, Animal; Endo | 1990 |
Thrombus formation on the aorta injured by angioplasty and its prevention with dilazep in atherosclerotic rabbits.
Topics: Angioplasty, Balloon; Animals; Aorta; Arteriosclerosis; Azepines; Body Weight; Cholesterol; Dilazep; | 1989 |
Assessment of regional myocardial perfusion by contrast echocardiography. II. Detection of changes in transmural and subendocardial perfusion during dipyridamole-induced hyperemia in a model of critical coronary stenosis.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, | 1989 |
MRI detection of myocardial perfusion changes by gadolinium-DTPA infusion during dipyridamole hyperemia.
Topics: Animals; Contrast Media; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, Anima | 1989 |
A sensitive model of venous thrombosis in rats.
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Disease Models, Animal; Female; Heparin; Ketanserin; | 1986 |
Effect of naftidrofuryl and dipyridamole on laser-induced thrombosis in rat mesenteric vessels.
Topics: Animals; Dipyridamole; Disease Models, Animal; Dose-Response Relationship, Drug; Furans; Male; Mesen | 1987 |
Effect of the cyclo-oxygenase inhibitor indobufen on platelet accumulation in prosthetic vascular grafts.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Dipyridamole; Disease Models, Animal; Dogs; Drug Evaluati | 1986 |
Impaired thickening of nonischemic myocardium during acute regional ischemia in the dog.
Topics: Acute Disease; Animals; Arterial Occlusive Diseases; Coronary Circulation; Coronary Disease; Diastol | 1985 |
Homocystinemia. Vascular injury and arterial thrombosis.
Topics: Adolescent; Adult; Animals; Blood Cell Count; Blood Coagulation; Blood Platelets; Blood Vessels; Dip | 1974 |
Effect of dipyridamole on retinal embolism associated with cardiopulmonary bypass surgery in the dog.
Topics: Animals; Blood Platelets; Dipyridamole; Disease Models, Animal; Dogs; Embolism; Extracorporeal Circu | 1974 |
Antithrombotic drugs and experimental thrombosis.
Topics: Animals; Aspirin; Dextrans; Dipyridamole; Disease Models, Animal; Drug Combinations; Fibrinolytic Ag | 1972 |
[Thromboembolism prevention after heart valve prosthesis in an experimental model].
Topics: Animals; Anticoagulants; Aspirin; Dipyridamole; Disease Models, Animal; Dogs; Heart Valve Prosthesis | 1972 |
Dipyridamole and aspirin tested against an experimental model of thrombosis.
Topics: Animals; Aspirin; Blood Vessels; Dipyridamole; Disease Models, Animal; Dogs; Hematoma; Hemorrhagic D | 1973 |
[Experimental study on drugs for the treatment of myocardial infarction].
Topics: Angiography; Animals; Benzyl Compounds; Body Weight; Carboxylic Acids; Dipyridamole; Disease Models, | 1972 |
Effect of a coronary vasodilator on the development of irreversible hemorrhagic shock.
Topics: Animals; Arteries; Blood Pressure; Blood Volume; Coronary Vessels; Dipyridamole; Disease Models, Ani | 1970 |
Platelet response to induction of hemorrhagic pancreatitis.
Topics: Animals; Anti-Bacterial Agents; Aspirin; Blood Cell Count; Dipyridamole; Disease Models, Animal; Dog | 1971 |